CJC-1295

Without DAC (Modified GRF 1-29): short half-life (~30 min), multiple daily doses, mimics natural pulses. With DAC: ~6-8 day half-life, weekly dosing, sustained GH/IGF-1 elevation. The pulsatile no-DAC version is generally preferred for research targeting physiological GH patterns.

Yes — this is the most common research stack. CJC-1295 (a GHRH analog) and Ipamorelin (a GHRP/ghrelin mimetic) act on different receptors and produce synergistic GH release greater than either alone. The combination is dosed together, typically 100mcg + 100-300mcg.

No-DAC: 100-300mcg per dose, 1-3x daily, often pre-bed and post-workout. With-DAC: 1-2mg once weekly. Doses are subcutaneous and titrated based on IGF-1 response and tolerability (flushing, transient dizziness).

Subcutaneous is the standard research route, with abdomen and thigh being common sites. SC produces reliable absorption with the established pharmacokinetic profile. IM is rarely used and offers no documented advantage.

Bacteriostatic water is the standard diluent. For a 2mg vial, 2mL of BAC water yields 1mg/mL (100mcg per 0.1mL). Swirl gently and store refrigerated. Reconstituted product is generally stable for 2-4 weeks at 2-8°C.

Common transient effects include injection site flushing, head rush, and tingling. Contraindicated in active malignancy due to GH/IGF-1 mitogenic concerns. Caution in subjects with diabetes (insulin sensitivity changes) or active retinopathy.